Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2025), 43, 2, (223-239), 10.1007/s40273-024-01417-4)

Julie A. Campbell; Glen J. Henson; Valery Fuh Ngwa; Hasnat Ahmad; Bruce V. Taylor; Ingrid van der Mei; Sudarshini Ramanathan; Todd A. Hardy; Cameron Shaw; Justin Garber; Richard Macdonell; Pamela McCombe; Nevin John; Suzanne Hodgkinson; Anneke van der Walt; Jeannette Lechner-Scott; Izanne Roos; Tomas Kalincik; William M. Carroll; Allan G. Kermode; Marzena Fabis-Pedrini; Helmut Butzkueven; Andrew J. Palmer

doi:10.1007/s40273-024-01461-0

Back

Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2025), 43, 2, (223-239), 10.1007/s40273-024-01417-4)

Journal article

Open access

Peer reviewed

Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2025), 43, 2, (223-239), 10.1007/s40273-024-01417-4)

Julie A. Campbell, Glen J. Henson, Valery Fuh Ngwa, Hasnat Ahmad, Bruce V. Taylor, Ingrid van der Mei, Sudarshini Ramanathan, Todd A. Hardy, Cameron Shaw, Justin Garber, …

PharmacoEconomics, Vol.43(2), p.241

2025

DOI: https://doi.org/10.1007/s40273-024-01461-0

Files and links (1)

pdf

Published385.06 kBDownload View

Open Access CC BY-NC V4.0

Abstract

Background Multiple sclerosis (MS) is a chronic autoimmune/neurodegenerative disease associated with progressing disability affecting mostly women. We aim to estimate transition probabilities describing MS-related disability progression from no disability to severe disability. Transition probabilities are a vital input for health economics models. In MS, this is particularly relevant for pharmaceutical agency reimbursement decisions for disease-modifying therapies (DMTs).

Details

Title: Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2025), 43, 2, (223-239), 10.1007/s40273-024-01417-4)
Authors/Creators: Julie A. Campbell - University of Tasmania
Glen J. Henson - University of Tasmania
Valery Fuh Ngwa - Medical Sciences Precinct, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
Hasnat Ahmad - University of Tasmania
Bruce V. Taylor - University of Tasmania
Ingrid van der Mei - University of Tasmania
Sudarshini Ramanathan - University of Tasmania
Todd A. Hardy
Cameron Shaw
Justin Garber
Richard Macdonell
Pamela McCombe
Nevin John
Suzanne Hodgkinson
Anneke van der Walt
Jeannette Lechner-Scott
Izanne Roos
Tomas Kalincik
William M. Carroll
Allan G. Kermode
Marzena Fabis-Pedrini
Helmut Butzkueven
Andrew J. Palmer - University of Tasmania
Publication Details: PharmacoEconomics, Vol.43(2), p.241
Publisher: Springer Nature; NORTHCOTE
Number of pages: 1
Identifiers: 991005884845007891
Murdoch Affiliation: Institute for Immunology and Infectious Diseases; Health Futures Institute; Personalised Medicine Centre
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: SDGs in the Output

Metrics

1 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.203 Neuromuscular Disorders; 1.203.147 Multiple Sclerosis
Web Of Science research areas: Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy
ESI research areas: Economics & Business